Arbutus Biopharma Corporation (NASDAQ:ABUS) shares, rose in value on Thursday, August 04, with the stock price up by 2.85% to the previous day’s close as strong demand from buyers drove the stock to $2.53.
Actively observing the price movement in the recent trading, the stock is buoying the session at $2.46, falling within a range of $2.25 and $2.46. The value of beta (5-year monthly) is 2.24. Referring to stock’s 52-week performance, its high was $6.50, and the low was $1.93. On the whole, ABUS has fluctuated by -14.58% over the past month.
With the market capitalization of Arbutus Biopharma Corporation currently standing at about $380.07 million, investors are eagerly awaiting this quarter’s results, scheduled for Aug 04, 2022.
Analysts have estimated the company’s revenue for the quarter at $6.77 million, with a low estimate of $3.21 million and a high estimate of $10.3 million. According to the average forecast, sales growth in current quarter could jump up 190.70%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $32.07 million, representing an increase of 191.90% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ABUS’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
5 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 1 analyst(s), 4 recommend it as a Buy and 0 called the ABUS stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ABUS currently trading nearly 1.59% and -1.01% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.03, while the 7-day volatility ratio is showing 5.73% which for the 30-day chart, stands at 5.49%. Furthermore, Arbutus Biopharma Corporation (ABUS)’s beta value is 2.30, and its average true range (ATR) is 0.14. The company’s stock has been forecasted to trade at an average price of $6.50 over the course of the next 52 weeks, with a low of $4.00 and a high of $9.00. Based on these price targets, the low is -58.1% off current price, whereas the price has to move -255.73% to reach the yearly target high. Additionally, analysts’ median price of $6.00 is likely to be welcomed by investors because it represents a decrease of -137.15% from the current levels.
A comparison of Arbutus Biopharma Corporation (ABUS) with its peers suggests the former has fared considerably weaker in the market. ABUS showed an intraday change of 2.85% in today’s session so far, and over the past year, it shrunk by -10.55%%. In comparison, Infinity Pharmaceuticals Inc. (INFI) has moved higher at 1.97% today and is down -73.46% over the past 12 months. Other than that, the overall performance of the S&P 500 during the today’s session so far shows that it lost -0.19%. Meanwhile, the Dow Jones Industrial Slipped by -0.25%.
Data on historical trading for Arbutus Biopharma Corporation (NASDAQ:ABUS) indicates that the trading volumes over the past 10 days have averaged 0.85 million and over the past 3 months, they’ve averaged 1.04 million. According to company’s latest data on outstanding shares, there are 148.43 million shares outstanding.
Nearly 27.11% of Arbutus Biopharma Corporation’s shares belong to company insiders and institutional investors own 29.80% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.14 million shares as on Jul 14, 2022, resulting in a short ratio of 5.22. According to the data, the short interest in Arbutus Biopharma Corporation (ABUS) stood at 3.46% of shares outstanding as of Jul 14, 2022; the number of short shares registered in Jun 14, 2022 reached 4.92 million. The stock has fallen by -36.76% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ABUS stock heading into the next quarter.